PTCT 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分較低，若以價值投資為目標，已經有長期投資部位可能需陸續減碼
PTCT 近期報酬表現
1.10%
Ptc therapeutics inc
2.35%
同產業平均
-0.21%
S&P500
與 PTCT 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
INSM | Insmed inc | 4 分 | 2 分 | 4 分 | 3 分 | 1 分 | |
BMRN | Biomarin pharmaceutical inc | 3 分 | 1 分 | 1 分 | 3 分 | 1 分 | |
SLRN | Acelyrin inc | - | 2 分 | 2 分 | 3 分 | 1 分 | |
SANA | Sana biotechnology inc | 2 分 | 3 分 | 3 分 | 2 分 | 1 分 | |
DNLI | Denali therapeutics inc | 4 分 | 3 分 | 2 分 | 3 分 | 1 分 |
- INSM Insmed inc價值 4 分趨勢 2 分波段 4 分籌碼 3 分股利 1 分查看更多
PTCT 公司資訊
PTC Therapeutics, Inc. is a global biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company has a diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. It has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD) a rare, life-threatening disorder. Its Upstaza, a gene therapy for the treatment of Aromatic L-Amino Decarboxylase (AADC) deficiency, a rare central nervous system (CNS) disorder. Its Tegsedi and Waylivra are for the treatment of rare diseases. Its Evrysdi, a treatment for spinal muscular atrophy (SMA).